ICCS 2021 - Presenting Companies

Presented by:

Cambridge Innovation Partners, USA
Siamab Therapeutics developed antibody-based therapeutics targeting cancer specific carbohydrate alterations seen in multiple solid tumors including ovarian, pancreatic, gastric and others. The company partnered two programs with large pharma companies and its lead program, targeting the STn antigen and formatted as an antibody-drug conjugate (ADC) entered clinical trials in January 2021.
Company:  Siamab Therapeutics
Speaker: Jeff Behrens
Title: CEO
​T.: +1 617 500-3455
E.: jeff@labshares.com
www.labshares.com
Aveta Biomics, a clinical-stage company, is developing cancer therapeutics that, unlike narrowly targeted drugs, address Higher-Order Epistasis prevalent in cancer to provide durable clinical benefits and higher response rates.  Current indications include Head & Neck Cancer and Glioblastoma.
Company: Aveta Biomics, Inc
Speaker: Parag G. Mehta, PhD
Title: CEO
​T.:+1 339 927 5994
E.: pmehta@avetabiomics.com
www.avetabiomics.com
Presented by:

The Wistar Institute, USA
Geneos leverages exquisitely personalized DNA immunotherapies to identify, design, manufacture, and deliver tumor specific neoantigen-targeted (TSNA-targeted) individualized cancer treatments.  
Company: Geneos Therapeutics
Speaker: Niranjan Y. Sardesai
Title: Co-Founder, President & CEO
​T.: +1 267-440-4232
E.: sardesai@geneostx.com
www.geneostx.com
Vetigenics is an animal health biopharmaceutical company committed to improving canine health through the development of entirely canine, safe and effective antibody-based immunotherapies to treat cancer, infectious disease and other chronic conditions. 
Company: Vetigenetics
Speaker: Adriann Sax
Title: Chief Executive Officer
​T.: +1 267-875-2283​
E.: asax@vetigenics.com
www.vetigenics.com
Presented by:

Montreal InVivo, Canada
At Immune Biosolutions (IBio), we strongly believe that biologics can transform and save lives. Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies in oncology and infectious diseases.
Company: Immune Biosolutions
Speaker: Frédéric Leduc
Title: CEO
T.: +1 (855) 346-3449 ext 700
E.: fleduc@ibiosolutions.com
www.immunebiosolutions.com
Cura Therapeutics is developing innovative immunotherapies to treat solid malignancies and infectious diseases. Cura Therapeutics harnesses cytokines and immune receptors to create multifunctional therapeutics with potent anti-cancer and anti-viral properties.
Company: Cura Therapeutics
Speaker: Dr. Claudia A. Penafuerte Diaz
Title: CEO
​T.: +1 514-714-2103
E.: claudiapd@curatherapeutics.com
www.curatherapeutics.com
Presented by:

​OBN, UK
Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.
Company: Crescendo Biologics
Speaker: Laurie Galson-Holt
Title: Associate Director of BD/IP
​T.: +44-(0) 1223-497-140
E.: conferences@crescendobiologics.com
www.crescendobiologics.com
Anastasis Biotech developed a Protein Drug Delivery platform applicable to oncology, virology and other diseases, with positive preclinical data against cancer stem cells.  It is aiming to raise £10M to expand R&D and start early phase clinical trials.
Company: Anastasis Biotec Ltd
Speaker: Prof. Agamemnon A. Epenetos
Title: Chairman and CEO
​T.: +44 7785 11 5010
E.: agamemnon@epenetos.com
www.anastasisbiotec.com
Presented by:
Oslo Cancer Cluster, Norway
Vaccibody AS, is a clinical-stage biopharmaceutical company. The Company develops vaccines for the treatment of cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells.
Company: Vaccibody
Speaker: Agnete Brunsvik Fredriksen
Title: President & Chief Scientific Officer
​T.: +47 454 89 233
E.: abfredriksen@vaccibody.com
www.vaccibody.com
Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor guided natural killer (TCR-NK) cell therapies for the treatment of solid cancers.
Company: Zelluna Immunotherapy AS
Speaker: Anders Holm
Title: COO & Head of BD
​T.: +47 402 00 475
E.: anders.holm@zelluna.com
www.zelluna.com
Presented by:

MatWin, France
OSE Immunotherapeutics is a French biotech developing innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The 5 clinical assets currently in the portfolio reflects the company's area of expertise: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets) and auto-Immunity & Inflammation.
Company: Ose Immunotherapeutics
Speaker: Jean-Jacques Mention 
​Title: Head of Scientific Business Development
​T.: +33 787 089 604
E.: jean-jacques.mention@ose-immuno.com
www.ose-immuno.com/en
DIVINCELL is a French Biotech Company, pioneering a novel drug delivery technology for targeted cancer therapies. Our drug candidates combine the potency of a nanocarrier with CRISPR and mRNA strategies, to specifically silence KRAS oncogene mutations and rescue tumor suppressor functions.
Company: DIVINCELL
Speaker: Gilles Divita 
Title: CEO
​T.: +33 650 740 869
​E.: divita.gilles@divincell-nanotechnology.fr
www.divincell-nanotechnology.fr
Presented by:

Biopôle, Switzerland
Antion Biosciences SA is a Swiss cell and gene engineering company developing highly innovative allogeneic therapies to cure diseases with significant unmet medical needs through ground-breaking cell engineering. Antion’s pipeline is focused on curing challenging cancer indications, HIV and sensory disorders with simple, easy to administer cell therapies.
Company: Antion Biosciences
Speaker: Sven Kili
Title: CEO
​T.: +41 (0) 22 310 63 70
E.: sven.kili@antion.ch
www.antion.ch
AMAL Therapeutics - Information is currently not available.